These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25377392)

  • 21. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
    Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
    Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 1 Mass Balance Study of
    Yu Y; Chung CH; Plotka A; Quinn K; Shi H; Pápai Z; Nguyen L; Wang D
    J Clin Pharmacol; 2019 Sep; 59(9):1195-1203. PubMed ID: 30964553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
    Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
    Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, mass balance, and metabolism of [
    Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H
    Cancer Chemother Pharmacol; 2024 Nov; 94(5):647-657. PubMed ID: 38507062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study investigation of metabolism, and disposition of [
    Liu Y; Liu L; Liu L; Wang T; Guo L; Wang Y; Gao Z; Shu Y
    Cancer Chemother Pharmacol; 2020 May; 85(5):907-915. PubMed ID: 32266457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
    Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line lenvatinib in patients with recurrent endometrial cancer.
    Vergote I; Powell MA; Teneriello MG; Miller DS; Garcia AA; Mikheeva ON; Bidzinski M; Cebotaru CL; Dutcus CE; Ren M; Kadowaki T; Funahashi Y; Penson RT
    Gynecol Oncol; 2020 Mar; 156(3):575-582. PubMed ID: 31955859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.